#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Uterine leiomyosarcoma Lymphoma Pemphigoid Follicular lymphoma stage III Ewing's sarcoma metastatic ROHHAD syndrome Prader-Willi syndrome Palmoplantar pustulosis Trigeminal neuralgia Eosinophilic granulomatosis with polyangiitis Multiple system atrophy Aplastic anaemia Astrocytoma Chronic graft versus host disease in liver Acute lymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency Burkitt’s lymphoma – Trials in Disease Congenital hypotransferrinaemia Chondrosarcoma metastatic – Diagnostics Medulloblastoma recurrent Sjogren’s syndrome – Trials in Disease Breast angiosarcoma – Treatment Chondrosarcoma – Trials in Disease Aicardi-Goutieres syndrome – Treatment Brain stem glioma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Letermovir Levomepromazine Hydrochloride LY3848575 RP3 Octocog Alfa Aluminium Glycerol Bgb-15025 Citrate Batoprotafib Alkaline Phosphatase, Bovine Alectinib Hydrochloride Sotalol Perflutren PEGZILARGINASE Specific Nucleic Acid Sna-Ebv Sotagliflozin 64CU-PSMA I&T Mosliciguat Benzocaine Mps-215 More therapies…

    Learn about Your Condition

    Lichen planus Right ventricular dysfunction Arrhythmia supraventricular Traumatic pain Renal disorder Andersen-Tawil syndrome Peyronie's disease Demyelination Haemorrhage intracranial Bronchitis Cardiac failure congestive Duchenne muscular dystrophy Plasma cell myeloma refractory Anal cancer stage II Ventricular extrasystoles More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic myeloid leukaemia

  • Study of Ponatinib for Patients with Resistant Chronic Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Ponatinib
    France Poland

  • Study of Bosutinib for Children with Newly Diagnosed or Resistant Chronic Myeloid Leukemia

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Bosutinib
    France Germany Italy The Netherlands Spain

  • Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Bosutinib
    • Imatinib
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Asciminib
    • Asciminib Hydrochloride
    Austria France Germany Greece Italy Poland +1

  • Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Nilotinib
    Bulgaria Czechia France Germany Greece Hungary +4

  • Comparison of Nilotinib versus Imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Imatinib
    • Nilotinib
    Italy The Netherlands
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!